title: [Current possibilities in pharmacotherapy of anxiety disorders in children and adolescents].
abstract: OBJECTIVE
  To assess the efficacy and safety of children tenoten in the treatment of children and adolescents with anxiety disorders.
  
  
  METHODS
  It was conducted a multicenter, double-blind, placebo-controlled trial of the drug tenoten children at a dose of 1 tablet 3 times a day for 12 weeks. The study included 98 patients (boys and girls from 5 to 15 years with a confirmed diagnosis of anxiety disorder), randomized into two groups: the first included 48 patients treated tenotenom children, in the second - 50 patients receiving placebo.
  
  
  CONCLUSIONS
  Tenoten children has a strong anti-anxiety effect both on the results of self-assessment of patients, and on the reports of parents. This anxiolytic activity of the drug manifested most significantly in children aged 5 to 7 years. In addition, in patients 8-15 years of treatment spent tenotenom children to regress the symptoms of anxiety disorders by anxiety subscales SCAS «Separation anxiety», «panic attacks and agoraphobia» and «social phobia». Throughout the course of treatment tenoten children have been no adverse events.
authors.affiliation: Pirogov Russian National Research Medical University, Moscow.
authors.forename: N N
authors.initials: NN
authors.lastname: Zavadenko
authors.affiliation: Mental Health Research Center, Moscow.
authors.forename: N V
authors.initials: NV
authors.lastname: Simashkova
authors.affiliation: Specialized Clinical Psychiatry Hospital #1, Krasnodar, Russia.
authors.forename: I N
authors.initials: IN
authors.lastname: Vakula
authors.affiliation: Pirogov Russian National Research Medical University, Moscow.
authors.forename: N Yu
authors.initials: NY
authors.lastname: Suvorinova
authors.affiliation: Mental Health Research Center, Moscow.
authors.forename: E E
authors.initials: EE
authors.lastname: Balakireva
authors.affiliation: Mental Health Research Center, Moscow.
authors.forename: M V
authors.initials: MV
authors.lastname: Lobacheva
mesh_terms: D000293:Adolescent; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000906:Antibodies / Q000008:administration & dosage / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000523:psychology; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D016584:Panic Disorder / Q000188:drug therapy; D010698:Phobic Disorders / Q000188:drug therapy; D011569:Psychiatric Status Rating Scales; D012647:Self-Assessment; D016896:Treatment Outcome
chemical_list: D014151:Anti-Anxiety Agents; D000906:Antibodies; C529609:tenoten